scPharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8106481059
USD
5.67
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About scPharmaceuticals, Inc. stock-summary
stock-summary
scPharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
scPharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip. The Company's products administered subcutaneously through the sc2Wear Infusor. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. The Company has completed two pivotal clinical studies, four exploratory clinical studies, and 12 human factor studies for Furoscix, and scCeftriaxone an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms.
Company Coordinates stock-summary
Company Details
2400 District Ave Ste 310 , BURLINGTON MA : 01803-5239
stock-summary
Tel: 1 617 51707301 781 3016706
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 27 Schemes (12.17%)

Foreign Institutions

Held by 30 Foreign Institutions (3.42%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Jack Khattar
Independent Chairman of the Board
Mr. John Tucker
President, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Director
Ms. Mette Agger
Independent Director
Ms. Minnie Baylor-Henry
Independent Director
Ms. Sara Bonstein
Independent Director
Dr. Mason Freeman
Independent Director
Mr. Frederick Hudson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
16 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 297 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.50

stock-summary
Return on Equity

317.48%

stock-summary
Price to Book

-13.95